diclofenac has been researched along with Myeloproliferative Disorders in 1 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liosi, ME | 1 |
| Ippolito, JA | 1 |
| Henry, SP | 1 |
| Krimmer, SG | 1 |
| Newton, AS | 1 |
| Cutrona, KJ | 1 |
| Olivarez, RA | 1 |
| Mohanty, J | 1 |
| Schlessinger, J | 1 |
| Jorgensen, WL | 1 |
1 other study available for diclofenac and Myeloproliferative Disorders
| Article | Year |
|---|---|
Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.
Topics: Humans; Janus Kinase 2; Janus Kinases; Ligands; Mutation; Myeloproliferative Disorders; Signal Trans | 2022 |